Subclinical disease activity in systemic lupus erythematosus: Immunoinflammatory markers do not normalize in clinical remission

被引:0
|
作者
Wais, T
Fierz, W
Stoll, T
Villiger, PM
机构
[1] Univ Hosp Bern, Dept Rheumatol & Clin Allergol, CH-3010 Bern, Switzerland
[2] Kantonsspital, Inst Clin Immunol & Microbiol, St Gallen, Switzerland
[3] AarReha Schinznach, Schinznach, Switzerland
关键词
cytokines; cytokine antagonists; disease activity; systemic lupus erythematosus; BILAG; adhesion molecules;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To correlate various laboratory measures in systemic lupus erythematosus (SLE) with the British Isles Lupus Assessment Group (BILAG) disease activity index, to search for organ-specific laboratory patterns and to compare with a control population. Methods. A cohort of 57 Caucasian outpatients fulfilling the American College of Rheumatology criteria for SLE and a control population of 17 patients admitted for coronarography were examined. Disease activity was assessed with BILAG index. Plasma samples were investigated for sCD44, interleukin 6 (IL-6), IL-10, IL-12, tumor necrosis factor-alpha (TNF-alpha), soluble TNF receptor-55 (sTNFR-55), sTNFR-75, IL-1-receptor antagonist, soluble intercellular adhesion molecule (sICAM), soluble vascular cell adhesion molecule (sVCAM), E-selectin, and neopterin as well as for C3, C4, dsDNA, and other conventional indicators. Results. Thirty-nine patients had inactive disease (total BILAG score less than or equal to 5), 18 patients had active SLE. Surprisingly, except for C-reactive protein (p < 0.001), no statistically significant difference of the laboratory indicators was found between patients with active and those with inactive SLE. However, there was a significant difference between SLE patients and controls for sTNFR-75 (p < 0.008). We found significant correlations between laboratory markers and some BILAG organ system scores, such as between IL-1ra and the musculoskeletal score (p < 0.003) and between sTNFR-55/sTNFR-75 and renal BILAG (p < 0.001, p < 0.004, respectively). Significant nonparametric correlations were revealed between C3 and C4 (p < 0.0001), and between sTNFR-75 and dsDNA, neopterin, sVCAM, sICAM and sTNFR-55 concentrations (p < 0.0001 for all), and between sTNFR-75 and IL-1ra (p < 0.006). Conclusion. Patients with SLE in clinical remission show ongoing systemic immunoinflammatory activity measured with a variety of cytokines, adhesion molecules, and other inflammatory markers. This indicates that laboratory measures may provide qualitatively different additional information to validated disease activity indexes such as the BILAG. Different laboratory markers correlate with disease activity in different organ systems. This suggests differences in pathogenic mechanisms in SLE depending on the organ system involved.
引用
收藏
页码:2133 / 2139
页数:7
相关论文
共 50 条
  • [31] Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE)
    Rina Mina
    Laura Schanberg
    Anne B Eberhard
    Marisa Klein–Gitelman
    Gloria Higgins
    Karen Onel
    Nora G Singer
    Kathleen O’Neil
    Lori Tucker
    Deborah Levy
    Wajeeha Yousaf
    Shannen Nelson
    Michael Beresford
    Ruben Cuttica
    Graciela Espada
    Angelo Ravelli
    Alberto Martini
    Edward Giannini
    Hermine I Brunner
    Pediatric Rheumatology, 9 (Suppl 1)
  • [32] Markers of Oxidative and Nitrosative Stress in Systemic Lupus Erythematosus Correlation With Disease Activity
    Wang, Gangduo
    Pierangeli, Silvia S.
    Papalardo, Elizabeth
    Ansari, G. A. S.
    Khan, M. Firoze
    ARTHRITIS AND RHEUMATISM, 2010, 62 (07): : 2064 - 2072
  • [33] Relationship between cytomegalovirus prevalence and markers of disease activity in systemic lupus erythematosus
    Krasselt, Marco
    Kippenhahn, Anne
    Baerwald, Christoph
    Pietsch, Corinna
    Seifert, Olga
    RHEUMATOLOGY, 2022, 61 (03) : 1288 - 1290
  • [34] Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis
    Inoh, M
    Tokuda, M
    Kiuchi, H
    Kurata, N
    Takahara, J
    ARTHRITIS AND RHEUMATISM, 1996, 39 (02): : 287 - 291
  • [35] Subclinical atherosclerosis in systemic lupus erythematosus
    Mercado, U
    Avendaño, L
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (06) : 1171 - 1172
  • [36] Subclinical atherosclerosis in systemic lupus erythematosus
    Ahmad, Y
    Bruce, IN
    JOURNAL OF RHEUMATOLOGY, 2004, 31 (05) : 841 - 843
  • [37] Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission
    Crispin, JC
    Alcocer-Varela, JC
    Martínez, A
    Richaud-Patin, Y
    Alarcón-segovia, D
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S123 - S123
  • [38] Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission
    Crispin, JC
    Alcocer-Varela, J
    de Pablo, P
    Martínez, A
    Richaud-Patin, Y
    Alarcón-Segovia, D
    LUPUS, 2003, 12 (05) : 386 - 393
  • [39] Subclinical choroidopathy in systemic lupus erythematosus
    Dias-Santos, Arnaldo
    Ferreira, Joana
    Pinheiro, Sofia
    Cunha, Joao Paulo
    Alves, Marta
    Papoila, Ana Luisa
    Moraes-Fontes, Maria Francisca
    Proenca, Rui
    ACTA OPHTHALMOLOGICA, 2019, 97
  • [40] Type I Interferons Are Associated with Subclinical Markers of Cardiovascular Disease in a Cohort of Systemic Lupus Erythematosus Patients
    Somers, Emily C.
    Zhao, Wenpu
    Lewis, Emily E.
    Wang, Lu
    Wing, Jeffrey J.
    Sundaram, Baskaran
    Kazerooni, Ella A.
    McCune, W. Joseph
    Kaplan, Mariana J.
    PLOS ONE, 2012, 7 (05):